![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/28/2906030/0/en/Dianthus-Therapeutics-Announces-Two-Poster-Presentations-for-DNTH103-at-the-10th-Congress-of-the-European-Academy-of-Neurology-EAN.html
https://www.globenewswire.com/news-release/2024/06/12/2897420/0/en/Dianthus-Therapeutics-Announces-FDA-Clearance-to-Initiate-Phase-2-Trial-of-DNTH103-in-Multifocal-Motor-Neuropathy-MMN.html
https://www.globenewswire.com/news-release/2024/05/30/2891159/0/en/Dianthus-Therapeutics-to-Participate-in-the-Jefferies-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/09/2879134/0/en/Dianthus-Therapeutics-Highlights-Recent-Business-Achievements-and-Reports-Q1-Financial-Results.html
https://www.globenewswire.com/news-release/2024/05/08/2878314/0/en/Dianthus-Therapeutics-to-Participate-in-the-Bank-of-America-Securities-2024-Health-Care-Conference.html
https://www.globenewswire.com/news-release/2024/05/03/2875361/0/en/Dianthus-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/04/11/2861388/0/en/Dianthus-Therapeutics-Announces-Oral-Presentation-for-DNTH103-at-the-2024-American-Academy-of-Neurology-AAN-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/04/05/2858744/0/en/Dianthus-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/03/21/2850603/0/en/Dianthus-Therapeutics-Highlights-Recent-Business-Achievements-and-Reports-Q4-and-FY2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/03/07/2842789/0/en/Dianthus-Therapeutics-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html